Vilanterol Trifenate

製品コードS3727 バッチS372702

印刷

化学情報

Synonyms

GW642444M Trifenate

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₂₄H₃₃Cl₂NO₅.C₂₀H₁₆O₂

分子量

774.77

CAS No.

503070-58-4

Solubility (25°C)*

体外

DMSO

100 mg/mL (129.07 mM)

Ethanol

10 mg/mL (12.9 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	7.5mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 150 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil	0.5mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Vilanterol trifenatate (GW642444M) is a novel inhaled long-acting beta2 adrenoceptor agonist with inherent 24-hour activity for once daily treatment of COPD and asthma.
in vitro	Vilanterol displays a subnanomolar affinity for the β2-AR that is comparable with that of salmeterol but higher than olodaterol, formoterol, and indacaterol. In cAMP functional activity studies, vilanterol demonstrates similar selectivity as salmeterol for β2- over β1-AR and β3-AR, but a significantly improved selectivity profile than formoterol and indacaterol. Vilanterol also shows a level of intrinsic efficacy that is comparable to indacaterol but significantly greater than that of salmeterol. In cellular cAMP production and tissue-based studies measuring persistence and reassertion, vilanterol has a persistence of action comparable with indacaterol and longer than formoterol. In addition, vilanterol demonstrates reassertion activity in both cell and tissue systems that is comparable with salmeterol and indacaterol but longer than formoterol. In human airways, vilanterol is shown to have a faster onset and longer duration of action than salmeterol, exhibiting a significant level of bronchodilation 22 h after treatment^[1].

製品説明

Vilanterol trifenatate (GW642444M) is a novel inhaled long-acting beta2 adrenoceptor agonist with inherent 24-hour activity for once daily treatment of COPD and asthma.

in vitro

Vilanterol displays a subnanomolar affinity for the β2-AR that is comparable with that of salmeterol but higher than olodaterol, formoterol, and indacaterol. In cAMP functional activity studies, vilanterol demonstrates similar selectivity as salmeterol for β2- over β1-AR and β3-AR, but a significantly improved selectivity profile than formoterol and indacaterol. Vilanterol also shows a level of intrinsic efficacy that is comparable to indacaterol but significantly greater than that of salmeterol. In cellular cAMP production and tissue-based studies measuring persistence and reassertion, vilanterol has a persistence of action comparable with indacaterol and longer than formoterol. In addition, vilanterol demonstrates reassertion activity in both cell and tissue systems that is comparable with salmeterol and indacaterol but longer than formoterol. In human airways, vilanterol is shown to have a faster onset and longer duration of action than salmeterol, exhibiting a significant level of bronchodilation 22 h after treatment^[1].

プロトコル(参考用のみ)

参考

[1] Slack RJ, et al. J Pharmacol Exp Ther. 2013, 344(1):218-30.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via β2-adrenoceptor [ Toxicol In Vitro, 2021, 77:105251]	PubMed: 34601065
Mechanism underlying β2-AR agonist-mediated phenotypic conversion of LPS-activated microglial cells [ J Neuroimmunol, 2019, 332:37-48]	PubMed: 30933849

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。